AVALO THERAPEUTICS, INC. Repayments of Debt
AVALO THERAPEUTICS, INC. (AVTX) reported Repayments of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2025-03-20
- AVALO THERAPEUTICS, INC. repayments of debt for the quarter ending 2024-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. repayments of debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. repayments of debt for the quarter ending 2023-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. repayments of debt for the quarter ending 2023-09-30 was $15.24M.
- AVALO THERAPEUTICS, INC. repayments of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AVALO THERAPEUTICS, INC. repayments of debt for fiscal 2023 was $21.24M.
- AVALO THERAPEUTICS, INC. repayments of debt for fiscal 2022 was $0.00.
- AVALO THERAPEUTICS, INC. repayments of debt for fiscal 2021 was $0.00.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month | Repayments of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $15.24M derived: sum of 2 quarters · filed 2025-03-20 | $21.24M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $15.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $21.24M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $6.00M 10-Q · filed 2024-08-12 | ||||
| 2022-12-31 | -$14.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$14.81M derived: sum of 2 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | $14.81M 10-K · filed 2023-03-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.81M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $14.81M 10-Q · filed 2023-08-03 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |